MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Roche Media News' source. Fri, 19 Mar 2010 16:14:40 +0100 http://www.medworm.com/index.php?rid=3376456&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-03-18.htm Leading late-stage pipeline and innovation strategy presented at investor conference. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3376456 Thu, 18 Mar 2010 06:00:00 +0100 3376456 http://www.medworm.com/index.php?rid=3356882&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-03-12.htm Roche announced today the topline results of a phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone. A preliminary assessment of safety performed by CALGB has shown adverse events that have been previously observed in pivotal trials with Avastin. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3356882 Fri, 12 Mar 2010 06:00:00 +0100 3356882 http://www.medworm.com/index.php?rid=3341013&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-03-08.htm Roche and Biogen Idec announced today their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3341013 Mon, 08 Mar 2010 06:00:00 +0100 3341013 http://www.medworm.com/index.php?rid=3320449&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-03-02.htm Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. The 698 shareholders in attendance, representing 143,055,648, or 89.4% of a total of 160,000,000 bearer shares, approved the 2009 Annual Report and financial statements. They also authorised a +20% increase in the dividend to 6.00 Swiss francs per share and non-voting equity. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3320449 Tue, 02 Mar 2010 12:30:00 +0100 3320449 http://www.medworm.com/index.php?rid=3304809&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-02-25.htm Roche announced today that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials with Avastin. Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3304809 Thu, 25 Feb 2010 06:00:00 +0100 3304809 http://www.medworm.com/index.php?rid=3296759&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-02-23.htm Roche announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in combination with Xeloda (capecitabine) or fluorouracil and cisplatin chemotherapy in patients with inoperable, advanced or metastatic gastric cancer (stomach cancer). The study, known as AVAGAST, did not meet its primary endpoint of extending overall survival in patients treated with Avastin in combination with chemotherapy compared to the same chemotherapy plus placebo. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3296759 Tue, 23 Feb 2010 06:00:00 +0100 3296759 http://www.medworm.com/index.php?rid=3296760&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-02-19.htm Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for people with either previously untreated (first-line) or previously treated (relapsed or refractory) CD20-positive chronic lymphocytic leukemia (CLL). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3296760 Fri, 19 Feb 2010 06:00:00 +0100 3296760 http://www.medworm.com/index.php?rid=3296761&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-02-11.htm Roche announced today that results from the first five Phase III clinical trials show that taspoglutide has met the primary end-points of reduction in blood glucose (blood sugar) in these studies. Roche’s taspoglutide, the first weekly human GLP-1 analogue in late stage development may improve treatment options for patients with type 2 diabetes. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3296761 Thu, 11 Feb 2010 06:00:00 +0100 3296761 http://www.medworm.com/index.php?rid=3296762&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-02-03.htm Record sales, double-digit growth in operating profit and Core Earnings per share – Dividend increase by 20% to 6.00 Swiss francs proposed - Group sales increase by 10% to 49.1 billion Swiss francs (8% in Swiss francs, 7% in US dollars). Both divisions gain market share. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3296762 Wed, 03 Feb 2010 06:00:00 +0100 3296762 http://www.medworm.com/index.php?rid=3296764&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-01-28b.htm Roche announced today that it will enter into a strategic alliance with Singapore’s scientific and medical institutions to set up a major new translational research hub in Singapore. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3296764 Thu, 28 Jan 2010 06:00:00 +0100 3296764 http://www.medworm.com/index.php?rid=3296763&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-01-28.htm Roche announced today that the European Commission has approved Herceptin (trastuzumab) in combination with chemotherapy for use in patients with HER2-positive metastatic stomach (gastric) cancer. The approval is based on the impressive results from the international ToGA trial, which showed that treatment with Herceptin significantly prolongs the lives of patients with this aggressive cancer. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3296763 Thu, 28 Jan 2010 06:00:00 +0100 3296763 http://www.medworm.com/index.php?rid=3214788&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-01-28b.htm Roche announced today that it will enter into a strategic alliance with Singapore’s scientific and medical institutions to set up a major new translational research hub in Singapore. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3214788 Thu, 28 Jan 2010 06:00:00 +0100 3214788 http://www.medworm.com/index.php?rid=3214787&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-01-28.htm Roche announced today that the European Commission has approved Herceptin (trastuzumab) in combination with chemotherapy for use in patients with HER2-positive metastatic stomach (gastric) cancer. The approval is based on the impressive results from the international ToGA trial, which showed that treatment with Herceptin significantly prolongs the lives of patients with this aggressive cancer. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3214787 Thu, 28 Jan 2010 06:00:00 +0100 3214787 http://www.medworm.com/index.php?rid=3296765&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2010-01-20.htm Roche is investing about 190 Mio Swiss Francs at its production sites in Kaiseraugst, Switzerland, and Mannheim, Germany, to manufacture a patient-friendly device which might for the first time allow patients to self-administer biological cancer medicines. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3296765 Wed, 20 Jan 2010 06:00:00 +0100 3296765 http://www.medworm.com/index.php?rid=3296766&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-actemra39-200px.jpg First-in-class biologic therapy, IL-6 receptor-inhibiting monoclonal antibody approved based on largest clinical development program in rheumatoid arthritis to date. Roche today announced that the United States (US) Food and Drug Administration (FDA) approved ACTEMRA (tocilizumab, RoACTEMRA in the European Union) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3296766 Mon, 11 Jan 2010 06:00:00 +0100 3296766 http://www.medworm.com/index.php?rid=3296767&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fbau1_200px.jpg Today Roche is unveiling the plans for Building 1, the new office building that the company intends to build at its Basel site. The project, which will accommodate some 1900 attractively designed workplaces, is the alternative to the “Twist 2 Spirals” scheme that the company decided not to continue a year ago. It meets all Roche’s requirements in terms of functionality and engineering. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3296767 Thu, 17 Dec 2009 13:00:00 +0100 3296767 http://www.medworm.com/index.php?rid=3296768&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-12-12.htm Today, Roche announced new long-term follow up-data from two large pivotal studies evaluating adjuvant Herceptin in HER2-positive early- stage breast cancer presented at the San Antonio Breast Cancer Symposium (SABCS). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3296768 Sat, 12 Dec 2009 15:45:00 +0100 3296768 http://www.medworm.com/index.php?rid=3081423&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-12-11.htm Roche today announced results from a phase III study (RIBBON 2) of Avastin (bevacizumab) in women with advanced HER2-negative breast cancer who had previously received chemotherapy as first-line treatment. The study showed that women who received Avastin in combination with commonly used chemotherapies as second-line treatment had a 28% improvement in the chance of being alive without the disease getting worse (progression-free survival or PFS) compared to chemotherapy alone. Adverse events were consistent with those previously reported for Avastin and no new Avastin safety findings were observed in the study. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3081423 Fri, 11 Dec 2009 18:30:00 +0100 3081423 http://www.medworm.com/index.php?rid=3077725&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-12-11b.htm Roche announced today that STAGE, a Phase III trial evaluating ocrelizumab as a treatment for seropositive rheumatoid arthritis (RA) patients with a previous inadequate response to methotrexate (MTX), met its primary efficacy endpoint. The study shows that patients treated with ocrelizumab in combination with MTX achieved the primary efficacy endpoint, which was a co-primary endpoint measured by an improvement in the signs and symptoms of their disease (ACR20 response) both at week 24 and week 48, compared to those treated with MTX alone. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3077725 Fri, 11 Dec 2009 06:00:00 +0100 3077725 http://www.medworm.com/index.php?rid=3073768&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2F0150540_cobas4800_200px.jpg Roche announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas 4800 System combines CE-marked in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3073768 Wed, 09 Dec 2009 17:00:00 +0100 3073768 http://www.medworm.com/index.php?rid=3069401&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-12-09.htm Roche to present new results that could offer a better future to women with early and very advanced breast cancer, at the CTRC-AACR San Antonio Breast Cancer Symposium (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3069401 Wed, 09 Dec 2009 06:00:00 +0100 3069401 http://www.medworm.com/index.php?rid=3065470&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-actemra43-200px.jpg Roche announced today at the 51st Meeting of the American Society of Hematology (ASH) in New Orleans, LA (USA) that the pivotal Phase III study CLL8 showed that patients with previously-untreated chronic lymphocytic leukemia (CLL) survived their disease longer when treated with MabThera/Rituxan (rituximab) compared to chemotherapy alone. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3065470 Tue, 08 Dec 2009 06:00:00 +0100 3065470 http://www.medworm.com/index.php?rid=3054835&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-12-04.htm Roche announced today that updated results of the pivotal phase III study, CLL8, will be one of many key presentations at the forthcoming 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3054835 Fri, 04 Dec 2009 06:00:00 +0100 3054835 http://www.medworm.com/index.php?rid=3014308&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-11-20.htm Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketing authorisation in Europe, has issued a negative opinion relating to the approval of Avastin (bevacizumab) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblastoma (GBM), the most aggressive type of primary malignant brain cancer. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=3014308 Fri, 20 Nov 2009 14:15:00 +0100 3014308 http://www.medworm.com/index.php?rid=2902431&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0050813-actemra-rheumatoid-200px.jpg Two-year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long-term use, patients with rheumatoid arthritis treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) plus methotrexate (MTX) suffered 81% less damage to their joints compared to those treated with MTX, the current standard therapy, alone1. For patients, this means that their joint damage is significantly reduced, and that they can therefore continue to enjoy their lives without the evolving disability usually associated with the disease. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2902431 Sat, 17 Oct 2009 21:00:00 +0100 2902431 http://www.medworm.com/index.php?rid=2892828&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-10-15.htm Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets ; Genentech integration progressing successfully; New Group leadership appointed (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2892828 Thu, 15 Oct 2009 05:00:00 +0100 2892828 http://www.medworm.com/index.php?rid=2826778&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-09-24.htm A detailed analysis of the Phase III ToGA study announced today revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2826778 Thu, 24 Sep 2009 11:10:00 +0100 2826778 http://www.medworm.com/index.php?rid=2826779&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-09-24b.htm Roche announced the winners of its global 3Rs Award Program - a unique and innovative program that helps to reduce and limit the use of animals in preclinical research - to recognise and reward innovation and continuous improvement in animal welfare within the Roche research organisation. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2826779 Thu, 24 Sep 2009 07:00:00 +0100 2826779 http://www.medworm.com/index.php?rid=2822612&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-09-23b.htm New data from several studies presented at ECCO 15 and ESMO 34 confirm unique benefits of Avastin (bevacizumab) and Xeloda (capecitabine) in treatment of colon cancer: Combination of Avastin with standard chemotherapy resulted in shrinkage or disappearance of liver metastases in 78% of patients with advanced colon cancer. A third of patients (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2822612 Wed, 23 Sep 2009 12:00:00 +0100 2822612 http://www.medworm.com/index.php?rid=2822613&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-09-23.htm New data from phase II Avastin study and a phase I extension study of highly selective BRAF inhibitor (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2822613 Wed, 23 Sep 2009 09:15:00 +0100 2822613 http://www.medworm.com/index.php?rid=2817500&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-09-22.htm Analysis of BRAIN study shows that patients may have a stabilisation or improvement in neurocognitive function and a reduction in steroid use. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2817500 Tue, 22 Sep 2009 08:45:00 +0100 2817500 http://www.medworm.com/index.php?rid=2792123&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fneuraminidase-and-tamiflu_200px.jpg 53% of patients with H5N1 infection survived when treated with Tamiflu compared with 12% of untreated patients. Rate of death was reduced by 37% in high-risk patients with severe seasonal flu compared with no treatment (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2792123 Sun, 13 Sep 2009 18:15:00 +0100 2792123 http://www.medworm.com/index.php?rid=2773761&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-09-08.htm William M. Burns, Juergen Schwiezer and Jonathan Knowles to retire – Pascal Soriot appointed COO Pharma Division and Daniel O’Day appointed COO Diagnostics Division – Jean-Jacques Garaud and Dan Zabrowski to become Members of Enlarged Executive Committee – Ian Clark appointed CEO Genentech (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2773761 Tue, 08 Sep 2009 05:00:00 +0100 2773761 http://www.medworm.com/index.php?rid=2760519&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-09-03b.htm Roche has been rated as the new Super Sector Leader in Healthcare on the Dow Jones Sustainability Index, placing Roche as the most sustainable healthcare company worldwide. Selection into the global Dow Jones Sustainability World Index as well as the pan-European Dow Jones STOXX Sustainability Index follows a thorough analysis of corporate economic, environmental and social performance, and takes into account elements such as corporate governance, risk management, access to medicines, climate change, supply chain standards, stakeholder engagement and labor practice. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2760519 Thu, 03 Sep 2009 09:00:00 +0100 2760519 http://www.medworm.com/index.php?rid=2760520&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-actemra43-200px.jpg Roche announced today that the European Commission has approved MabThera (rituximab) for use in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the most common form of the disease in adults. The approval is supported by the impressive results from REACH, the largest randomised clinical trial ever reported in previously-treated CLL. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2760520 Thu, 03 Sep 2009 05:00:00 +0100 2760520 http://www.medworm.com/index.php?rid=2663501&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-avastin-0050343-200px.jpg Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) plus interferon alpha for people with metastatic renal cell carcinoma, the most common type of kidney cancer. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2663501 Mon, 03 Aug 2009 05:00:00 +0100 2663501 http://www.medworm.com/index.php?rid=2655735&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-07-30.htm Roche announced today that the Phase III study CRUISE showed Lucentis (ranibizumab injection) improved vision in patients with swelling in the retina (macular edema) due to central retinal vein occlusion (RVO). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2655735 Thu, 30 Jul 2009 16:00:00 +0100 2655735 http://www.medworm.com/index.php?rid=2647555&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-avastin-0050343-200px.jpg Physicians will be able to offer more patients Avastin-based treatment options (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2647555 Wed, 29 Jul 2009 05:00:00 +0100 2647555 http://www.medworm.com/index.php?rid=2632693&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-07-24b.htm Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation for the use of MabThera (rituximab) in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2632693 Fri, 24 Jul 2009 09:30:00 +0100 2632693 http://www.medworm.com/index.php?rid=2628576&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-07-23.htm Integration of Genentech progressing rapidly; full-year outlook raised; Group sales up 2 billion to 24 billion Swiss francs, an increase of 10% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2628576 Thu, 23 Jul 2009 05:00:00 +0100 2628576 http://www.medworm.com/index.php?rid=2616270&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-07-20.htm Roche announced today results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination with intravenous oxaliplatin (XELOX) immediately after surgery, which show that patients with colon cancer taking XELOX live disease free for longer compared to those taking the commonly used intravenous chemotherapy combination 5-fluorouracil/leucovorin (5-FU/LV). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2616270 Mon, 20 Jul 2009 05:00:00 +0100 2616270 http://www.medworm.com/index.php?rid=2593992&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-07-13.htm Roche announced today that SATURN, a pivotal Phase III study, met a key secondary endpoint of extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva(erlotinib) immediately after their initial chemotherapy. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2593992 Mon, 13 Jul 2009 05:00:00 +0100 2593992 http://www.medworm.com/index.php?rid=2566744&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-07-02.htm Roche announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2566744 Thu, 02 Jul 2009 16:00:00 +0100 2566744 http://www.medworm.com/index.php?rid=2481858&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-06-11.htm RA patients with enhanced response identified (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2481858 Thu, 11 Jun 2009 08:15:00 +0100 2481858 http://www.medworm.com/index.php?rid=2481859&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-06-10.htm Up to 56% of patients with active rheumatoid arthritis (RA) treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) for over two years, will achieve disease remission, according to new data presented today at the European League Against Rheumatism (EULAR) congress. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2481859 Tue, 09 Jun 2009 22:01:00 +0100 2481859 http://www.medworm.com/index.php?rid=2466364&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-06-09.htm Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2466364 Tue, 09 Jun 2009 05:00:00 +0100 2466364 http://www.medworm.com/index.php?rid=2450985&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-06-01.htm Roche announced today results from a phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for patients with advanced melanoma whose cancer harbours the BRAF mutation (known as mutation-positive). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2450985 Mon, 01 Jun 2009 10:30:00 +0100 2450985 http://www.medworm.com/index.php?rid=2450986&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-05-31.htm Data from the ToGA study presented today at the American Society for Clinical Oncology Annual Meeting in Orlando, Florida showed that adding Herceptin (trastuzumab) to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin) prolongs the lives of patients with this aggressive cancer on average by nearly three months to 13.8 months. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2450986 Sun, 31 May 2009 14:30:00 +0100 2450986 http://www.medworm.com/index.php?rid=2444715&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-05-30b.htm Phase III ATLAS study achieves a new milestone in treating advanced lung cancer (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2444715 Sat, 30 May 2009 15:00:00 +0100 2444715 http://www.medworm.com/index.php?rid=2444716&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-05-30.htm Results suggest future trials may hold promise for Avastin as early-stage colon cancer treatment even though C-08 study does not meet primary endpoint (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2444716 Sat, 30 May 2009 13:00:00 +0100 2444716 http://www.medworm.com/index.php?rid=2432948&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0050813-actemra-rheumatoid-200px.jpg Roche announced today that new two-year data from the LITHE study demonstrate that ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) continues to be highly effective at inhibiting joint structural damage and maintaining consistently high remission rates. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2432948 Mon, 25 May 2009 05:00:00 +0100 2432948 http://www.medworm.com/index.php?rid=2494174&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0067419_200px.jpg More than 500 scientific abstracts to be presented across 20 types of cancers. Results could significantly improve the way cancer is treated for patients with inoperable stomach cancer; advanced melanoma; lung and breast cancers. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2494174 Thu, 14 May 2009 22:00:00 +0100 2494174 http://www.medworm.com/index.php?rid=2409809&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-05-12.htm Roche today announced a new donation to the World Health Organization (WHO) of 5.65 million courses of treatment of the antiviral drug Tamiflu (oseltamivir). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2409809 Tue, 12 May 2009 05:00:00 +0100 2409809 http://www.medworm.com/index.php?rid=2385055&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-05-02.htm Roche today confirms that the World Health Organisation (WHO) has requested deployment of the “Rapid Response Stockpile.” The stockpile is being deployed to countries in need at the discretion of WHO. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2385055 Sat, 02 May 2009 15:45:00 +0100 2385055 http://www.medworm.com/index.php?rid=2378805&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-04-30.htm Roche tonight confirms that it has been in contact with the World Health Organization (WHO) following the announcement to move to influenza pandemic alert phase 5. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2378805 Wed, 29 Apr 2009 22:55:00 +0100 2378805 http://www.medworm.com/index.php?rid=2378806&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-04-29.htm Roche today confirms that it is working closely with the World Health Organization (WHO) and Governments around the world to make the oral antiviral medication Tamiflu available to patients in need following the increased reports of outbreaks of swine flu. The WHO and US CDC report Tamiflu is active against this new swine flu virus A(H1N1). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2378806 Wed, 29 Apr 2009 07:15:00 +0100 2378806 http://www.medworm.com/index.php?rid=2355533&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-04-22.htm Roche today announced the results of the first phase III trial evaluating the use of Avastin (bevacizumab) plus chemotherapy (FOLFOX) for the treatment of colon cancer immediately following surgery (adjuvant therapy) compared to chemotherapy alone. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2355533 Wed, 22 Apr 2009 05:00:00 +0100 2355533 http://www.medworm.com/index.php?rid=2336300&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-04-16.htm Group sales up 8% in local currencies and 7% in Swiss francs to 11.6 billion Swiss francs (-1% in US dollars); Roche completes transaction to take full ownership of Genentech - key decisions on organisational structure and management appointments taken; Full-year outlook to be updated to include impact of Genentech transaction and communicated with half-year results (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2336300 Thu, 16 Apr 2009 05:00:00 +0100 2336300 http://www.medworm.com/index.php?rid=2336301&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-04-15.htm Roche today announced that it will join forces with Novo Nordisk and the World Diabetes Foundation (WDF) in Novo Nordisk’s five-year program called “Changing Diabetes in Children”. Roche Diabetes Care will actively endorse humanitarian activities in this project which is starting in Tanzania, Uganda, Cameroon, Guinea-Conakry and the Democratic Republic of Congo. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2336301 Wed, 15 Apr 2009 06:45:00 +0100 2336301 http://www.medworm.com/index.php?rid=2336302&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-04-14.htm Following the completion of the Genentech transaction Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) today announced the successful start of the integration. Building on the long-standing and trustful relationship of the two companies, senior leaders from Genentech and Roche have made considerable progress in a short period of time to set the course for the integration. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2336302 Tue, 14 Apr 2009 21:00:00 +0100 2336302 http://www.medworm.com/index.php?rid=2313883&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Flightcycler_200px.jpg Roche announced today that its new LightCycler test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) is now available with the CE Mark, allowing it to be sold for clinical use in the European Union. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2313883 Thu, 02 Apr 2009 05:00:00 +0100 2313883 http://www.medworm.com/index.php?rid=2313884&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-03-26b.htm Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: DNA) announced today that Roche has completed its acquisition of Genentech pursuant to a short-form merger in which Genentech became a wholly-owned member of the Roche Group. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2313884 Thu, 26 Mar 2009 16:30:00 +0100 2313884 http://www.medworm.com/index.php?rid=2290628&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-03-26.htm Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that its wholly-owned subsidiary, Roche Investments USA Inc., completed its tender offer for the publicly held shares of Genentech (NYSE: DNA). The offer expired at midnight, New York City time, at the end of Wednesday, March 25. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2290628 Thu, 26 Mar 2009 06:00:00 +0100 2290628 http://www.medworm.com/index.php?rid=2279610&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-03-18.htm Roche today announced results from a major international study which show that adding Herceptin (trastuzumab) to standard chemotherapy significantly prolongs lives of patients with HER2-positive stomach (gastric) cancer. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2279610 Wed, 18 Mar 2009 06:00:00 +0100 2279610 http://www.medworm.com/index.php?rid=2270944&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fcellavista_innovatis_200px.jpg Roche today announced that it has signed a definite agreement under which Roche will acquire 100% of innovatis, a privately held company based in Bielefeld, Germany. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2270944 Mon, 16 Mar 2009 06:00:00 +0100 2270944 http://www.medworm.com/index.php?rid=2265564&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-03-12.htm Roche (SWX: ROG.VX; RO.S) and Genentech (NYSE: DNA) announced today that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US$95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2265564 Thu, 12 Mar 2009 06:00:00 +0100 2265564 http://www.medworm.com/index.php?rid=2253523&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-her2-200px.jpg The Breast International Group (BIG) in collaboration with Roche announced today that women with HER2 positive early breast cancer continue to benefit from Herceptin (trastuzumab) several years after treatment completion and as a result enjoy a longer life disease free. The patients were treated for one year with Herceptin and followed up for four years. These data from the HERA study were presented at the Primary Therapy in Early Breast Cancer conference in St. Gallen, Switzerland. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2253523 Wed, 11 Mar 2009 06:00:00 +0100 2253523 http://www.medworm.com/index.php?rid=2253524&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-03-10.htm Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. The 703 shareholders in attendance, representing 144,334,099, or 90.2% of a total of 160,000,000 bearer shares, approved the 2008 Annual Report and financial statements. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2253524 Tue, 10 Mar 2009 12:30:00 +0100 2253524 http://www.medworm.com/index.php?rid=2243210&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-03-06.htm Roche (SWX: ROG.VX; RO.S) announced today that it has increased its offer price for all outstanding publicly-held shares of Genentech (NYSE: DNA) to US$ 93 per share and extended the offer to 12:00 midnight, New York City time, on Friday, March 20, 2009. All other terms and conditions of the tender offer remain unchanged. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2243210 Fri, 06 Mar 2009 17:00:00 +0100 2243210 http://www.medworm.com/index.php?rid=2218736&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-actemra43-200px.jpg Roche announced today that the European Commission has approved MabThera (rituximab) in combination with chemotherapy for use in patients with previously-untreated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia to affect adults. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2218736 Fri, 27 Feb 2009 06:00:00 +0100 2218736 http://www.medworm.com/index.php?rid=2192543&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0022297_hepatitis_200px.jpg New data presented today showed that, for the first time, doctors can predict which hepatitis B patients treated with Pegasys (peginterferon alfa-2a) have the highest chance to achieve a positive treatment outcome - and even a clinical cure. The study results represent an important step forward, as some patients will now be able to feel confident during their Pegasys treatment about the likelihood of beating the disease. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2192543 Mon, 16 Feb 2009 06:00:00 +0100 2192543 http://www.medworm.com/index.php?rid=2170588&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-02-09.htm Roche announced today that it is commencing a cash tender offer for all outstanding publicly-held shares of Genentech for US$86.50 per share. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2170588 Mon, 09 Feb 2009 21:24:00 +0100 2170588 http://www.medworm.com/index.php?rid=2158110&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-02-04.htm Double-digit sales growth - Core Earnings per share at constant exchange rates above 2007 level - Dividend increase by 9% to 5.00 Swiss francs proposed (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2158110 Wed, 04 Feb 2009 06:00:00 +0100 2158110 http://www.medworm.com/index.php?rid=2153781&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-tarceva-200px.jpg Roche today announced interim results from a phase III study (ATLAS) in patients with advanced non small cell lung cancer (NSCLC). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2153781 Tue, 03 Feb 2009 06:00:00 +0100 2153781 http://www.medworm.com/index.php?rid=2145446&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-01-30.htm Roche announced today that it intends to commence a cash tender offer for all outstanding publicly-held shares of Genentech at US$ 86.50 per share. Roche, which currently owns 55.8% of the Genentech outstanding shares, expects to commence the tender offer within approximately two weeks. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2145446 Fri, 30 Jan 2009 06:00:00 +0100 2145446 http://www.medworm.com/index.php?rid=2139006&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2009-01-28.htm Roche’s Board of Directors and Corporate Executive Committee is delighted about the extension of the shareholders’ pooling agreement which the successors of the the company founder Fritz Hoffmann-La Roche announced today. As a result, the families Hoffmann and Oeri will continue to hold the majority of the company’s shares. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2139006 Wed, 28 Jan 2009 07:00:00 +0100 2139006 http://www.medworm.com/index.php?rid=2126554&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-bau97-200px.jpg At a ceremony attended by people involved in the project and other guests, the foundation stone was laid today for the new Research & Development building at Roche Basel. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2126554 Fri, 23 Jan 2009 10:00:00 +0100 2126554 http://www.medworm.com/index.php?rid=2126555&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-actemra43-200px.jpg Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation for the use of MabThera (rituximab) with any chemotherapy combination as a first-line treatment for chronic lymphocytic leukaemia (CLL), the most common form of adult leukaemia. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2126555 Fri, 23 Jan 2009 06:00:00 +0100 2126555 http://www.medworm.com/index.php?rid=2117489&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-actemra39-200px.jpg Roche today announced that the European Commission has approved RoACTEMRA (tocilizumab, known as Actemra outside of the EU), to treat patients with rheumatoid arthritis (RA). RoACTEMRA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderate to severe RA who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2117489 Wed, 21 Jan 2009 06:30:00 +0100 2117489 http://www.medworm.com/index.php?rid=2079098&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fcobas-s-201_200px.jpg The United States Food & Drug Administration (FDA) today approved a new nucleic acid test from Roche to screen donated blood for HIV-1 Group M RNA, hepatitis C RNA and hepatitis B DNA in a single, automated assay. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2079098 Wed, 31 Dec 2008 07:30:00 +0100 2079098 http://www.medworm.com/index.php?rid=2054897&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-actemra43-200px.jpg Roche announced today that MabThera (rituximab) can significantly inhibit structural damage to joints in patients with early rheumatoid arthritis (RA) who have not been treated with methotrexate (MTX), the current standard of care for RA treatment. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2054897 Fri, 19 Dec 2008 06:30:00 +0100 2054897 http://www.medworm.com/index.php?rid=2029638&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0007554-herceptin-200px.jpg About 70% of women with locally advanced HER2-positive breast cancer were free of their disease three years after initiation of therapy when treated with Herceptin plus chemotherapy before surgery, compared to only around 50% of patients receiving pre-operative chemotherapy alone. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2029638 Thu, 11 Dec 2008 20:00:00 +0100 2029638 http://www.medworm.com/index.php?rid=2029639&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2008-12-10.htm New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients allowing women to live longer or disease free for longer if the medicines are given before and after surgery as well as in advanced stages of disease. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2029639 Wed, 10 Dec 2008 06:30:00 +0100 2029639 http://www.medworm.com/index.php?rid=2022906&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0017460-knowles-200px.jpg Prof. Jonathan Knowles, Head of Group Research and member of the Corporate Executive Committee of Roche, will retire from Roche at the end of 2009. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2022906 Mon, 08 Dec 2008 06:30:00 +0100 2022906 http://www.medworm.com/index.php?rid=2019488&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0051398-mabthera-200px.jpg Significant new data from two pivotal phase III studies, to be presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco this week, show that patients with chronic lymphocytic leukaemia (CLL) treated with MabThera (rituximab) in combination with chemotherapy live considerably longer without their disease progressing, compared to patients treated with chemotherapy alone. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2019488 Sun, 07 Dec 2008 03:30:00 +0100 2019488 http://www.medworm.com/index.php?rid=2019490&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0022297_hepatitis_200px.jpg Roche announced today that the European Commission has approved Pegasys (peginterferon alfa-2a [40 KD]) plus Copegus (ribavirin) for the retreatment of hepatitis C patients who were not successfully treated with an initial course of interferon alpha (pegylated or non-pegylated), either alone or in combination with ribavirin. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2019490 Thu, 04 Dec 2008 06:30:00 +0100 2019490 http://www.medworm.com/index.php?rid=2019489&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-actemra39-200px.jpg Roche today announced that the U.S. Food and Drug Administration (FDA) has provided further guidance on the requirements for the Biologics License Application (BLA) for Actemra (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2019489 Thu, 04 Dec 2008 06:30:00 +0100 2019489 http://www.medworm.com/index.php?rid=2000621&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0026227-200px.jpg On 1st December for the sixth consecutive year, Roche will be holding a sponsored worldwide walk to raise money to help orphans and children in need. With their participation, the Roche employees demonstrate their solidarity and ongoing commitment to help support children in Malawi and childrens’ organisations in their own countries. All funds raised by employees are matched by Roche. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=2000621 Mon, 01 Dec 2008 08:00:00 +0100 2000621 http://www.medworm.com/index.php?rid=1985994&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-brain-0000520-200px.jpg Roche and Memory Pharmaceuticals today announced that the two companies have signed a definitive merger agreement for Roche to fully acquire Memory in an all-cash transaction at a price of approximately USD 50 million. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1985994 Tue, 25 Nov 2008 06:50:00 +0100 1985994 http://www.medworm.com/index.php?rid=1985995&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Froche-areal-basel-200px.jpg Roche has decided for technical reasons not to continue with its office high-rise in the form originally planned. It became apparent during the project design phase that the building would not be capable of satisfying key functional requirements despite the high investment. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1985995 Mon, 24 Nov 2008 10:00:00 +0100 1985995 http://www.medworm.com/index.php?rid=1985996&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-avastin-0050343-200px.jpg Third study confirming the benefit of Avastin in breast cancer shows that Avastin can be effectively combined with commonly used chemotherapies (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1985996 Mon, 24 Nov 2008 06:30:00 +0100 1985996 http://www.medworm.com/index.php?rid=1977536&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0050813-actemra-rheumatoid-200px.jpg Roche today announced that the European Committee on Human Medicinal Products (CHMP) has given a positive recommendation for RoActemra (tocilizumab, known as Actemra outside of the EU), in combination with methotrexate (MTX), for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA) who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1977536 Fri, 21 Nov 2008 13:15:00 +0100 1977536 http://www.medworm.com/index.php?rid=1956655&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-attinger-200px.jpg Effective January 1, 2009, Per-Olof Attinger will be appointed Head of Corporate Communications and Member of the Enlarged Corporate Executive Committee, reporting to Severin Schwan, CEO of the Roche Group. He succeeds Rolf Schläpfer, who – as previously announced – has decided to leave Roche at the end of the year to pursue his career outside the company. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1956655 Thu, 13 Nov 2008 06:30:00 +0100 1956655 http://www.medworm.com/index.php?rid=1941212&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-tarceva-200px.jpg Roche today announced that the SATURN (SequentiAl Tarceva in UnResectable NSCLC) study met its primary endpoint of progression free survival. The study showed that Tarceva (erlotinib), when given in first line maintenance - immediately following initial treatment with platinum-based chemotherapy - , significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1941212 Fri, 07 Nov 2008 06:30:00 +0100 1941212 http://www.medworm.com/index.php?rid=1909461&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0050813-actemra-rheumatoid-200px.jpg Roche announced today that the innovative new therapy ACTEMRA (tocilizumab) can significantly inhibit structural damage to joints in patients with rheumatoid arthritis (RA) – this is a critical measure of effectiveness of an RA treatment. ACTEMRA was also found to improve the patients’ physical function after one year of therapy and to significantly increase the disease remission rate. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1909461 Mon, 27 Oct 2008 06:30:00 +0100 1909461 http://www.medworm.com/index.php?rid=1892691&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2008-10-21.htm Sales by the Roche Group in the first nine months of 2008 increased by 6% in local currencies (-2% in Swiss francs; 13% in US dollars) to 33.3 billion Swiss francs. Excluding Tamiflu pandemic sales to governments and corporations, sales rose 10% (2% in Swiss francs; 17% in US dollars). The rise in the Swiss franc against most currencies, particularly against the US dollar, resulted in Swiss franc growth being eight percentage points lower than growth in local currencies. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1892691 Tue, 21 Oct 2008 05:00:00 +0100 1892691 http://www.medworm.com/index.php?rid=1884538&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmedia%2Fmedia_releases%2Fmed-cor-2008-10-17.htm Roche today announced the winners of its global 3Rs Award Program which rewards innovation and continuous improvement in animal welfare within the Roche research organization. The award is based on the 3Rs concept, which means Replacing animal tests where possible, Reducing the number of animals required and Refining existing scientific practices as well as animal care and husbandry. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1884538 Fri, 17 Oct 2008 05:30:00 +0100 1884538 http://www.medworm.com/index.php?rid=1857466&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0051398-mabthera-200px.jpg Roche announced today that a Phase III study investigating MabThera (rituximab) in combination with chemotherapy has shown a significant improvement in progression free survival in patients with relapsed or refractory Chronic Lymphocytic Leukaemia (CLL), the most common form of adult leukaemia. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1857466 Tue, 07 Oct 2008 05:30:00 +0100 1857466 http://www.medworm.com/index.php?rid=1854156&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-avastin-0050343-200px.jpg Phase III data shows evidence of potential benefit for patients with advanced lung cancer. Roche today announced topline results from the phase III BeTa Lung study investigating the addition of Avastin (bevacizumab) to Tarceva (erlotinib) compared with Tarceva alone for the second-line treatment of patients with advanced non-small cell lung cancer (NSCLC), the most common form of lung cancer. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1854156 Mon, 06 Oct 2008 05:30:00 +0100 1854156 http://www.medworm.com/index.php?rid=1849110&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0081597-200px.jpg Genentech, Inc. (NYSE: DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX: ROG) have entered into a collaboration agreement, including a licence from GlycArt to Genentech, for the joint development and commercialization of GlycArt’s GA101 molecule. The companies will be developing GA101, a humanized anti-CD20 monoclonal antibody engineered to increase both direct- and immune-mediated target cell death, for the potential treatment of hematological malignancies and other oncology-related B-cell disorders such as non-Hodgkin’s lymphoma. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1849110 Fri, 03 Oct 2008 05:30:00 +0100 1849110 http://www.medworm.com/index.php?rid=1842078&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fsite_penzberg_200px.jpg Roche is investing 215 million Swiss francs (136 million euros) in research, development and production at its site in Penzberg, near Munich. The money will be used to construct a multi-purpose building for Roche Diagnostics. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1842078 Wed, 01 Oct 2008 05:30:00 +0100 1842078 http://www.medworm.com/index.php?rid=1838828&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-138196-tingueli-wetzel.jpg Roche reaffirms its strong and lasting commitment to the Museum. The Board of Directors of the Tinguely Museum has appointed Roland Wetzel as the new Museum Director. Currently working at the Fine Arts Museum in Basel as a management assistant and curator, 43 year-old Roland Wetzel will take up his new post on April 1st, 2009. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1838828 Tue, 30 Sep 2008 11:30:00 +0100 1838828 http://www.medworm.com/index.php?rid=1827338&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-0050813-actemra-rheumatoid-200px.jpg Roche today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the Biologics License Application (BLA) for Actemra (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA). (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1827338 Thu, 18 Sep 2008 16:00:00 +0100 1827338 http://www.medworm.com/index.php?rid=1795627&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-cor-2008-09-16 Avastin (bevacizumab) remains the only biologic to provide overall survival (OS) benefit when used as first-line treatment in combination with chemotherapy for patients with K-Ras wild type metastatic colorectal cancer (mCRC). Avastin`s strong position was confirmed today following new data from a cetuximab [Erbitux] study presented at the 33rd Congress of the European Society for Medical Oncology (ESMO). ¿K-Ras wild-type¿ describes the normal gene status seen in around 60% of colorectal cancer patients where the K-Ras oncogene has not mutated. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1795627 Tue, 16 Sep 2008 06:30:00 +0100 1795627 http://www.medworm.com/index.php?rid=1784302&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-cor-2008-09-10 More than 100 Roche abstracts have been accepted for the biggest cancer congress in Europe, the European Society for Medical Oncology (ESMO), which opens in Stockholm on Friday (12th September) (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1784302 Wed, 10 Sep 2008 05:30:00 +0100 1784302 http://www.medworm.com/index.php?rid=1784303&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-cor-2008-09-08 After more than 11 years with Roche, Rolf Schläpfer, Head of Corporate Communications, has decided to resign from his position by the end of the year and to pursue his career outside the company. His successor will be announced in due course. Rolf Schläpfer has agreed to oversee important projects ad interim beyond the date of his resignation. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1784303 Mon, 08 Sep 2008 05:30:00 +0100 1784303 http://www.medworm.com/index.php?rid=1784304&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-cor-2008-08-29 Roche will be presenting the commission for the fifth work in the Roche Commissions series to the Japanese composer Toshio Hosokawa tomorrow, Saturday, August 30th. A presentation ceremony will be held at Roche Forum Buonas near Lucerne to commence the fifth round of this innovative cultural project. Toshio Hosokawa`s work will be performed as a world premiere in summer 2010 at the Culture and Convention Centre Lucerne (KKL) as part of the Lucerne Summer Festival. It will have its New York premiere at Carnegie Hall in the following concert season. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1784304 Fri, 29 Aug 2008 07:00:00 +0100 1784304 http://www.medworm.com/index.php?rid=1784305&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-cor-2008-08-15b Today Roche gave a progress report on the reconstruction of Chocos, a village in the Peruvian Andes that was heavily affected by a devastating earthquake on 15 August 2007. After immediately sending emergency and first aid materials to the region, Roche decided to make a lasting difference by helping to reconstruct the destroyed village. The project is funded by Roche and by ReAct, the Roche Employee Action and Charity Trust. ReAct, Roche and the inhabitants of Chocos work together to provide the expertise needed to rebuild the village. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1784305 Fri, 15 Aug 2008 07:00:00 +0100 1784305 http://www.medworm.com/index.php?rid=1784306&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-cor-2008-08-15 Roche and Meda, an international specialty pharmaceutical company based in Solna (Stockholm), Sweden, have signed an agreement for the sale of four Roche pharmaceutical products to Meda. The world wide product rights for Marcoumar (Anticoagulant), Torem (Loop diuretic), Tilcotil (painful musculoskeletal disorders) and Aurorix (Depression) are being transferred to Meda for a total amount of 120 million Euros (approximately 195 million Swiss francs at current exchange rates). The transaction is expected to close in late 2008 and is subject to standard closing conditions. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1784306 Fri, 15 Aug 2008 05:30:00 +0100 1784306 http://www.medworm.com/index.php?rid=1784307&cid=s_37968_34_f&fid=37968&url=http%3A%2F%2Fwww.roche.com%2Fmed-cor-2008-08-13 A hundred students of science, music and arts from more than seventy European universities have teamed up in Salzburg this week to uncover the common ground of creativity in the arts and science, and attend Kontinente a new festival within the Salzburg festival focusing on the works of a contemporary composer. The Roche Continents project, which was established in 2007 (with the Scelsi concertos) is a collaboration between the Salzburg Festival and Roche, aiming at encouraging young people to explore contemporary music and get familiar with the unfamiliar. (Source: Roche Media News) Roche Media News organizations http://www.medworm.com/rss/comments.php?id=1784307 Wed, 13 Aug 2008 08:00:00 +0100 1784307